Skip to main content
. 2015 Jul 14;5(7):e007231. doi: 10.1136/bmjopen-2014-007231

Figure 3.

Figure 3

Stage I: Short-term evaluation of 0.75–3.0 mg/day alprazolam on biochemical variables related to chronic stress. Stage II: Short-term evaluation of 0.75–3.0 mg/day alprazolam on cognitive and clinical variables related to chronic stress. Stage III: Intermediate-term evaluation of low alprazolam doses in cognitive, clinical and quality of life indicators (GEMA, Gador study of Estres Modulation by Alprazolam).